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Inverse Relationship between PSA and IL-8 in Prostate
Cancer: An Insight into a NF-kB-Mediated Mechanism
Yong Xu1, Fang Fang2, Daret K. St. Clair1, William H. St. Clair2*
1 Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky, United States of America, 2 Department of Radiation Medicine, University of Kentucky,
Lexington, Kentucky, United States of America

Abstract
Background: Prostate specific antigen (PSA) is traditionally used as an indicator for the presence of prostate cancer (PCa)
and radiotherapy is generally used to treat inoperable and locally advanced PCa. However, how cellular PSA level is
associated with sensitivity of PCa to radiotherapy is unknown. The previous finding that the RelB-based NF-kB alternative
pathway differentially regulates PSA and interleukin-8 (IL-8) in aggressive PCa has directed our attention to the role of RelB
in the response of PCa to radiotherapy.
Methodology/Principal Findings: RelB and its targets PSA and IL-8 in PCa cells were manipulated by ectopic expression in
PCa cells with a low endogenous level of RelB (LNCaP) and by RNAi-based knock-down in PCa cells with a high constitutive
level of RelB (PC3). The effects of RelB, PSA and IL-8 on the response of PCa to radiation treatment were examined in vitro
and in xenograft tumors. RelB regulates PSA and IL-8 in an inverse manner. When the cellular levels of PSA and IL-8 were
directly modulated by genetic manipulations or by the addition of recombinant proteins, the results demonstrate that upregulation of IL-8 enhanced radioresistance of PCa cells and concurrently down-regulated PSA. In contrast, up-regulation of
PSA resulted in reduced radioresistance with concurrent down-regulation of IL-8.
Conclusion/Significance: RelB plays a critical role in the response of PCa to radiotherapy and the inverse expression of IL-8
and PSA. The results identify a previously unrecognized relationship between IL-8 and PSA in the response of PCa cells to
radiotherapy.
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IL-8, a NF-kB-activated cytokine, is thought to be an important
factor in tumor metastasis and resistance to treatment [6–9]. The
circulating level of IL-8 is increased in advanced PCa at the stage
when the tumor no longer responds to anti-androgen therapies
[10]. Furthermore, expression of IL-8 enhances PCa androgenindependent metastasis [11,12]. Thus, the expression of IL-8 may
have significant prognostic value for PCa growth and response to
therapy. The present study investigated the roles of PSA and IL-8
in the radioresistance of PCa cells using in vitro and in vivo
approaches. The results reveal the previously unrecognized role of
IL-8 and PSA as determinants of the sensitivity of PCa to
radiotherapy.

Introduction
Prostate cancer (PCa) is the second most common malignancy
in North America and the second leading cause of cancer deaths in
U.S. men [1]. The serum concentration of PSA in men is used as
an indicator of disease of the prostate and increased PSA level is
used extensively as a biomarker of PCa. Radiotherapy is generally
used to treat early-stage, inoperable and locally advanced PCa.
However, whether cellular PSA could be used as indicators of
tumor responsiveness to radiotherapy is unknown.
NF-kB, an inflammatory responsive transcription factor, plays
an important role in tumorigenesis and resistance to therapyinduced cytotoxicity [2]. The high constitutive level of NF-kB in
cancers has been implicated as a major protective mechanism
against cancer treatment [3]. Thus, inhibition of NF-kB is being
considered as a target for enhancing the efficacy of conventional
chemotherapy and radiotherapy [4]. We have previously demonstrated that overexpression of RelB, a NF-kB member, suppressed
PSA expression in androgen-responsive LNCaP PCa cells, which
suggests a negative effect of NF-kB on PSA expression [5].
Serendipitously, we also have found that in animals bearing RelBoverexpressed LNCaP tumors, the circulating level of IL-8 was
increased.
PLoS ONE | www.plosone.org

Results
NF-kB up-regulates IL-8 but down-regulates PSA in PCa
cells
Activation of the NF-kB pathway is thought to be a major factor
contributing to the development of the radioresistance of cancer
cells. Because RelA and RelB are the two major members of the
NF-kB family found in PCa cells [13], we determined the effects of
RelA and RelB on IL-8 and PSA expression and radiosensitivity
1
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using multiple approaches for activation and inactivation of the
NF-kB pathway. First, RelA or RelB was overexpressed in LNCaP
cells by transfection with its respective cDNA constructs. As shown
in Fig. 1A, the levels of PSA were decreased by both RelA and
RelB when they were overexpressed in LNCaP cells. In contrast,
the levels of IL-8 were increased by both RelA and RelB. The
corresponding effect of RelA and RelB on radioresistance of
LNCaP cells was greater with overexpression of RelB.
Second, the endogenous RelA and RelB in LNCaP cells were
knocked-down using the RNA interference (RNAi) approach. RelA
siRNA or RelB siRNA was transfected into LNCaP cells to silence
their expression. As shown in Fig. 1B, the levels of PSA inversely
correlate to the reduced levels of both RelA and RelB, with a greater
effect observed for RelB. The levels of IL-8 were similarly decreased
in RelA and RelB knocked-down in the cells, with a greater effect
for RelA siRNA. Radiosensitivity of LNCaP cells was enhanced by
reducing either RelA or RelB (Fig. 1B). The cell survival in control
siRNA was reduced to 46.3% by radiation treatment, whereas the
cell survival was further reduced to 30.1% or 23.4% when RelA or
RelB was knocked-down. Statistical analysis showed the significant
differences of RelA siRNA and RelB siRNA as compared to control
siRNA. Thus, knock-down of RelB nearly doubled the cell killing
effect of radiation. However, the killing of RelB siRNA plus
radiation was slightly less than the combined effects of siRNA alone
and radiation alone. Thus, it is possible the second hit to cells that

were already dead may account for this observation. Third, RelA
and RelB were inhibited by blocking their nuclear translocation to
further confirm their roles in the regulation of PSA and IL-8
expressions. Mutant construct for IkBa (IkBaM) [14] or p100
(p100M) [15] was transfected into LNCaP cells to block RelA:p50
dimer or RelB:p52 dimer nuclear translocation, respectively. As
shown in Fig. 1C, the responses of PSA and IL-8 expressions were
similar to the results obtained from the RNAi method (Fig. 1B).
Thus, blockage of either RelA or RelB nuclear translocation
efficiently enhanced the radiosensitivity of LNCaP cells.

PSA inversely correlates to IL-8 in PCa cells
PSA and IL-8 have been shown to be important biomarkers in
multiple stages of PCa progression. We have shown that upregulation of IL-8 but down-regulation of PSA is associated with
increasing tumorigenicity of PCa cells [5]. Two PCa cell lines were
used to validate the correlation of PSA to IL-8: LNCaP, an
androgen responsive PCa cell line, expresses PSA and a low level
of IL-8; PC3, an androgen-independent PCa cell line, expresses a
high level of IL-8, but PSA is undetectable. After transfection of an
IL-8 cDNA expression construct into LNCaP cells, the relative
levels of PSA were quantified. As IL-8 expression increased,
cellular PSA levels dose-dependently decreased. In addition,
knocking- down PSA by PSA siRNA resulted in dose-dependent
increases in the cellular IL-8 levels (Fig. 2A). Furthermore,

Figure 1. Differential regulation of PSA and IL-8 by NF-kB in LNCaP cells. To manipulate NF-kB function, RelA and RelB cDNA constructs (A),
RelA and RelB siRNAs (B), and RelA and RelB nuclear translocation inhibitors (IkBaM and p100M) (C) were transfected into LNCaP cells prior to IR
treatment. The levels of transfected proteins and the related target PSA were quantified by Western blots (top panel). The Western images were
normalized by b-actin and then normalized by a vehicle control. Fold changes are indicated. IL-8 concentrations in media were quantified by an Elisa
kit (middle panel). Cell survivals were quantified using Trypan blue exclusion assay (bottom panel). * (p,0.05) and ** (p,0.01) indicate statistical
significances as compared to the vehicle control.
doi:10.1371/journal.pone.0032905.g001

PLoS ONE | www.plosone.org
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expressing PSA in PC3 cells led to reduction in IL-8 production.
However, there were no expressions of PSA in PC3 cells even
when IL-8 was knocked- down by siRNA (Fig. 2B). It has been
shown that NF-kB activation can mediate the prosurvival pathway
of IL-8:CXCR2 signaling [16]. To probe whether NF-kB may be
a mediator for the observed inverse relationship between IL-8 and
PSA, a NF-kB-luciferase reporter construct was co-transfected into
LNCaP cells with the PSA expression construct or PSA siRNA. As
shown in Fig. 2C, over- expression of PSA suppressed but PSA
deficiency enhanced NF-kB-mediated transcriptional activation.

determine their roles in the radiosensitivity of PCa cells. Increasing
IL-8 in LNCaP cells by either treating the cells with IL-8 protein
(Fig. 3A, top panel) or stably transfecting IL-8 cDNA in the cells
(Fig. 3A, low panel) resulted in a decrease of PSA levels and
sensitivity to radiation. In addition, lentiviral-based shRNA stable
knock-down of PSA in LNCaP cells resulted in increasing IL-8
levels and reducing radiosensitivity of the cells (Fig. 3B). To further
verify the roles of PSA and IL-8 in radiosensitivity of PCa cells,
PSA and IL-8 in PC3 cells were modulated by transfection of PSA
cDNA and IL-8 siRNA, respectively. Lentivirus-based expression
of PSA and knock-down of IL-8 in PC3 cells led to high levels of
PSA, reduction of IL-8 levels and increased radiosensitivity of PC3
cells (Fig. 3C). Together, these results indicate the inverse
relationship between IL-8 and PSA in PCa cells and suggest that
PSA and IL-8 have opposite effects on the radiosensitivity of PCa
cells.

PSA and IL-8 play opposite roles in the radiosensitivity of
PCa cells
Being NF-kB regulated gene products, PSA and IL-8 may play
an important role in the responses of PCa to radiotherapy. We
therefore manipulated the levels of PSA and IL-8 to directly

Figure 2. Reverse correlation of PSA and IL-8 in PCa cells. To manipulate PSA and IL-8 in PCa cells, LNCaP cells were transfected with an IL-8
cDNA construct and a PSA siRNA (A); PC3 cells were transfected with PSA cDNA construct and IL-8 siRNA (B). To test whether PSA influences NF-kB
transcriptional activation, a NF-kB-luciferase reporter construct was co-transfected with a PSA expression construct or PSA siRNA and a b-gal
expression construct into LNCaP cells. The luciferase responses were normalized with b-gal activities (C). PSA and IL-8 levels were quantified by
Western blots with normalization as described in Figure 1.
doi:10.1371/journal.pone.0032905.g002
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Figure 3. The effects of PSA and IL-8 on radioresistance of PCa cells. To determine the roles of PSA and IL-8 in radiosensitivity of PCa cells,
LNCaP cells were treated with IL-8 protein or stably transfected with IL-8 cDNA (A) and stably transducted with PSA shRNA lentivirus (B); PC3 cells
were stably transducted with PSA cDNA and IL-8 shRNA lentivirus (C). The levels of PSA were quantified by Western blots and the levels of IL-8 were
quantified by either Western blots or an Elisa kit. Cell survival was quantified by Trypan blue exclusion assays. Western blots were normalized with
controls and cell survival fraction analysis as described in Figure 1.
doi:10.1371/journal.pone.0032905.g003

experiment. However, IR only stopped the growth of RelB
expressing tumors for 20 days post-radiation, after which tumor
regrowth was observed. The experiment was terminated because
some mice in the radiated groups developed poor health
conditions implicated by clinical signs of systemic disease such as
dehydration, labored or shallow breathing, and losing 20% of their
maximum weight. After the tumors were removed, the expression
of RelB and levels of PSA and IL-8 in the tumor tissues were
quantified using an appropriate antibody for each protein.
Consistent with the high levels of RelB identified in the RelBexpressed tumors, IL-8 was increased but PSA was decreased in
the same tumor tissues (Fig. 4D).

Up-regulation of RelB reduces radiosensitivity of LNCaP
tumor in vivo
The above data obtained in vitro implicate RelB and it targets,
IL-8 and PSA, as having an important role in the radiosensitivity
of PCa. To verify the role of RelB in the radiosensitivity of PCa
and the inverse relationship between IL-8 and PSA expressions in
vivo, a stable RelB-expressing LNCaP clone was generated (Fig. 4A)
and subcutaneously injected into the flanks of nude male mice;
tumor growth was monitored for 50 days by measuring tumor size.
Tumor growth rate change was quantified by the time (days)
required for tumor size to reach a volume of 500 mm3. Fig. 4B
shows that the average time for the control group to reach
500 mm3 was 5466.7 days. Tumor growth rate increase in the
RelB-expressed clone took 4365.6 days to reach 500 mm3.
Animals with an average tumor size of 500 mm3 were randomized
into two groups for 1) treatment with fractionated radiation (3 Gy
radiation per day for 5 days) and 2) sham controls. Mice were
humanely sacrificed when tumors reached the maximum size of
2000 mm3. As shown in Fig. 4C, in the unradiated mice, vector
control tumors grew from 500 mm3 to 2000 mm3 in 2563.7 days,
whereas the tumor expressing RelB reached the same size in
1462.3 days. Ionizing radiation (IR) effectively prevented the
growth of control tumor within the 50-day period of the

PLoS ONE | www.plosone.org

Down-regulation of RelB enhances radiosensitivity of PC3
tumors
To further validate the protective role of RelB against radiation,
a lentivirus-based RelB siRNA PC3 clone was selected (Fig. 5A)
and injected into the flanks of nude male mice. In the control
siRNA group, the average time for a tumor to reach 500 mm3 was
1162.1 days, whereas the average time in the RelB knock-down
group extended to 2665.1 days (Fig. 5B). Tumors were treated
with IR at 365 Gy after tumor reached an average size of
500 mm3. In unradiated control mice, the tumor size in the
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Figure 4. The effect of overexpression of RelB on radioresistance of LNCaP tumors. A stable RelB expressed LNCaP clone was
characterized by Western blots (A). The RelB/LNCaP cells were injected into male mice for tumor formation and growth reaching to 500 mm3 (B). The
tumors were treated IR (563 Gy) and tumor volumes were measured until they reached 2000 mm3 (C). RelB, PSA and IL-8 levels were quantified in
the tumor lysates and statistically analyzed (D). Statistical significances of tumor volumes (C) and the levels of the target proteins (D) between RelB
expressed and vehicle control in both no- IR and IR treated groups are indicated.
doi:10.1371/journal.pone.0032905.g004

control siRNA group quickly grew from 500 mm3 to 2000 mm3
within 1563.1 days. Compared to the control siRNA group,
tumor growth in the RelB knock-down group was significantly
slower than in the control siRNA group. IR inhibited the growth
of the control tumor with the trend to regrowth after 20 days post
IR. Interestingly, IR not only controlled tumor regrowth, but it
also reduced tumor size in the RelB siRNA group (Fig. 5C). The
differences observed in vivo are not simple reflections of growth
differences in vitro because there are no significant decreases in cell
growth when RelB was stably knocked-down in PC-3 cells. Thus,
the radiosensitization effect by knock-down of RelB is due to
inhibition of radiation-inducible NF-kB activation. The effects of
siRNA-mediated knock-down of RelB were confirmed by Western
blot analyses of RelB and IL-8 in the tumor tissues (Fig. 5D).
These results support the role of RelB in the response of PCa to
radiotherapy.

prostatic gland and leakage of PSA from the lumen to the
interstitial liquid and into the general circulation. [18,19]. In
addition, PCa can be present in the absence of elevated serum
PSA levels [20]. Indeed, there are no detectible levels of PSA in
androgen-independent PCa cell lines, such as PC3 and DU-145.
Although PSA is used as a biomarker in the diagnosis of PCa, its
biological function has not been fully elucidated. The results from
the present study demonstrate that cellular PSA level may be an
important indicator of PCa cell response to IR. Down-regulation
of PSA in androgen responsive LNCaP cells leads to reduced
radiosensitivity and expression of PSA in androgen-independent
PC3 cells results in enhanced radiosensitivity, suggesting that PSA
plays an important role in the response of PCa cells to
radiotherapy.
IL-8, a pro-inflammatory cytokine, uniquely expresses in
androgen-independent PCa cells but not in androgen-responsive
PCa cells [8,21]. Elevated IL-8 levels in advanced PCa have been
considered to be a major factor contributing to cancer cell
proliferation and survival after treatments [6,12]. The present
study reveals an interesting relationship between PSA and IL-8 in
the response of PCa cells to radiotherapy. The inverse relationship
between PSA and IL-8 expressions confounds a conclusion that
the observed changes in radiosensitivity of PCa are dependent on
PSA level; alternatively, the observed effect of PSA may be

Discussion
PSA is an androgen receptor (AR)-regulated serine protease
produced by prostate epithelial cells [17]. Although an elevated
serum PSA level correlates with the presence of PCa, many
factors, such as inflammation, infection, prostatic hyperplasia as
well as tissue processes, lead to certain loss of integrity of the
PLoS ONE | www.plosone.org
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Figure 5. The effect of knock-down RelB on radioresistance of PC3 tumors. A lentivirus-based RelB siRNA knock-down PC3 clone was
characterized by Western blots (A). The RelB shRNA/PC3 cells were injected into male mice for tumor formation (B). The tumors were treated with IR
(365 Gy) when tumor volumes reached 500 mm3 and tumors were allowed to grow to 2000 mm3 (C). RelB and IL-8 levels were quantified in the
tumor lysates and statistically analyzed (D). Statistical analysis for tumor volumes and the levels of target proteins as described in Figure 4.
doi:10.1371/journal.pone.0032905.g005

remains through a variety of androgen-independent mechanisms
[28]. Thus, ablation of AR function is the goal of first-line therapy.
Although these treatments are initially effective, recurrent tumors
arise with restored AR activity [29] or even with other ligand
binding receptors [30]. As an AR target, PSA screening monitors
the management of PCa. However, the presence of AR is not
adequate for predicting the efficiency of therapy because the level
of PSA may be also regulated by many other factors. A large
number of studies have demonstrated that both AR and NF-kB
signaling are important factors in the progression of PCa. The
restoration of AR activity in the absence of androgen is considered
a mechanism for PCa as it progresses to the hormone-refractory
stage [29]. In addition, NF-kB-mediated IL-6-stat3 activation is
thought to be another important mechanism for tumor metastasis
[31]. However, cross talk between the two signal pathways is
elusive. The results of this study demonstrate that overexpression
of RelB increased the cellular level of IL-8 but decreased the level
of PSA, suggesting that NF-kB target genes may be differentially
regulated by different members of the NF-kB family or that RelB
may serve as co-activator for IL-8 transcription while serving as a
negative co-regulator for PSA transcription. It has been shown
that the combination of RelB and aryl hydrocarbon receptor
(AhR) can activate transcription from a RelB/AhR element
uniquely located upstream from the IL-8-kB site [32]. It has also
been shown that NF-kB suppresses PSA transcription through an

mediated, in part, by a change in IL-8 level. The data presented in
this report directly demonstrate the role of IL-8 in the
radiosensitivity of PCa cells. Together, these results highlight the
intricate relationship between IL-8 and PSA, which contribute to
the response of PCa cells to radiotherapy.
NF-kB is constitutively active in many cancers, and it functions
in the up-regulation of antiapoptotic and oncogenic genes
[10,22,23]. Another important biological function of NF-kB is
related to the coordination of the innate and adaptive immune
responses that maintain cellular defense systems [3]. Inhibition of
NF-kB is therefore considered a useful complement to traditional
chemo- or radio-therapy. NF-kB consists of five Rel-related
proteins, which contain the RelA/p50 heterodimer-mediated
classical pathway and the RelB/p52 heterodimer-mediated
alternative pathway [3,10,13]. RelB is uniquely expressed in
advanced PCa cells and the RelB-based alternative pathway plays
an important role in the tumorigenesis of PCa [24,25]. We have
previously shown that selective inhibition of the alternative
pathway remarkably suppresses the tumorigenicity of PCa cells
[5,26,27]. The results from the present study demonstrate that
RelB may also play a critical role in the radioresistance of PCa
cells, in part, via an inverse effect on the expressions of IL-8 and
PSA.
AR activity is essential for PCa initiation and progression. Even
when PCa progresses to hormone-refractory stages, AR signaling
PLoS ONE | www.plosone.org

6

March 2012 | Volume 7 | Issue 3 | e32905

The Roles of PSA and IL-8 in Radiosensitivity

androgen receptor element located in the promoter region of a
gene [33]. Our finding is consistent with the possibility that NF-kB
not only has the capacity to activate its target gene but also to
inhibit its target gene depending on the composition of factors
affecting transcription.
Radiation therapy causes growth arrest and death in cancer
cells either by direct ionization of DNA or by generation of
reactive oxygen species (ROS) that can damage the DNA. It has
been shown that genotoxic agents, including IR, induced by
double-strand breaks (DSBs) stimulate the NF-kB pathway to
generate positive feedback loops via cytokine production, which in
turn activates DNA repair mechanisms [34–36]. The cytokineactivated NF-kB pathway can also lead to induction of antioxidant
enzymes, which protect cancer cells against ROS generating
therapeutics. Our previous studies, which demonstrate that
inhibition of NF-kB and its antioxidant target, manganese
superoxide dismutase (MnSOD), remarkably increase radiosensitivity of aggressive prostate cancer cells [5,25], are consistent with
the finding for this later mechanism.
The mechanism by which PSA may modulate cellular response
to radiation therapy remains unknown. It is possible that the
observed negative effect of PSA is due, in part, to the increase in
IL-8 level when PSA is reduced. Indeed, reverse association of
PSA and IL-8 was observed in both androgen-responsive and
androgen-independent PCa cells, suggesting that the increased
ratio of IL-8 to PSA contributes to radioresistance of PCa cells.
Future study to determine how the level of PSA affects the
production of IL-8 would be interesting.
In summary, the present study uses complementary experimental approaches to show that RelB contributes to radioresistance of
PCa cells and inversely regulates IL-8 and PSA expressions. The
inverse relationship between IL-8 and PSA levels is predictive for
the response of PCa cells to radiation, suggesting the potential to
enhance radiotherapy of PCa by direct modulation of IL-8 and/or
PSA levels. This is the first experimental evidence to implicate the
role of PSA in the radiotherapy of PCa cells. Insights obtained
from the present study provide a scientific basis for the use of IL8/PSA ratio as a cellular indicator for the management of PCa
cells by radiation.

cDNA were cloned between EcoR V – Not I sites in pCMV-Sport6
vector; P100M construct was provided by Dr. Shao-Cong Sun’s
lab at Pennsylvania State University [37]. P100M sequence was
cloned between Hind III – Xba I sites in pCMV4 vector; IkBaM
construct was provided by Dr. Veronique Imbert’s lab, Adhésion
cellulaire, Hôpital de Sainte Marguerite, Marseille, France. IkBa
(S32-36A) mutant sequence was cloned at EcoR V site in pcDNA
3.1 vector. All the vectors contain a CMV promoter and were used
without any inducible condition. The stable transfected clones
were selected by neomycin resistance. To knock-down endogenous
RelA, RelB, PSA and IL-8 in PCa cells, the specific siRNA (Santa
Cruz Biotech.) was transfected. Lentivirus-based shRNA constructs (Open Biosystems) were used to stably knock-down the
targets according to manufacturer’s instructions. The levels of
proteins were confirmed by Western blots. A NF-kB-luciferase
reporter plasmid containing four copies of NF-kB elements linked
to a SV40 promoter in pGL3 vector (Promega) was previously
constructed [25]. The reporter construct was co-transfected with
the PSA expression vector or PSA siRNA (Santa Cruz Biotech.)
and b-galactosidase (b-gal) construct into LNCaP cells to
determine the effect of PSA on NF-kB transcriptional activation.

Animals
Four-week old male NCRNU (nu/nu athymic nude) mice were
purchased from Taconic (Hudson). 1.86106 PCa cells mixed with
Matrigel (BD Biosciences) were injected into the right flanks of the
mice. Tumor volumes were calculated weekly using a standard
formula (A6B26.52; A and B represent the diagonal tumor
lengths). The tumor tissues were collected, and 100 mg tissues were
lysed to quantify protein levels using Western blots. Animal
experiment procedures were approved by the Institutional Animal
Care and Use Committee of the University of Kentucky, Approval
Protocol No. 01077M2006.
Western blot. To quantify protein levels, cell and tissue
extracts were separated using SDS-PAGE, 8% (w/v)
polyacrylamide gel, and then transferred onto a nitrocellulose
membrane and blotted with primary antibodies against RelA,
RelB, P100, IkBa, PSA, IL-8 and b-actin. A goat anti-mouse IgGHRP conjugated secondary antibody was used to detect RelA,
PSA, IL-8, and b-actin. Other proteins were detected using a goat
anti-rabbit
IgG-HRP
conjugated
secondary
antibody.
Immunoblots
were
visualized
by
an
enhanced
chemiluminescence detection system (ECL, Amersham
Pharmacia Biotech.).

Materials and Methods
Cell culture and treatment
Human prostate carcinoma LNCaP and PC3 (American Type
Culture Collection, ATCC) were grown and maintained in RPMI
media with 10% fetal bovine serum. Cells were treated with IR
using a 250 kV X-ray machine (Faxitron X-ray Corp.) with peak
energy of 130 kV, 0.05 mm Al filter, at a dose of 0 to 5 Gy. To
examine the effect of IL-8 on radiation responses, LNCaP cells
were pretreated with IL-8 (BD Biosciences) at concentrations of 0
to 100 pg/ml for 12 h prior to radiation exposure. Radiosensitivity of PCa cells was quantified using cell survival fraction
determined by Trypan blue exclusion assay, as previously
described [26].

IL-8 quantification
Cultured media were collected at the end of experimental
procedures. The levels of IL-8 secreted from cultured cells were
quantified using an IL-8 Elisa kit (BD Biosciences) according to the
manufacturer’s protocol.

Statistical data analyses
Multiple independent experiments were performed for each set
of data. Images in Western blots were quantified using Carestream
Molecular Imaging software (Carestream Health Inc.). Statistical
significance was analyzed using one-way ANOVA and Tukey’s
Multiple Comparison Test, followed by data analysis with
Graphpad Prism.

Cell transfection
To express RelA, RelB, PSA, IL-8, p100M and IkBaM proteins
in PCa cells, expression constructs coding these proteins were
used. RelA (p65) expression construct is a gift from the laboratory
of Nancy Rice (NIH); the p65 cDNA were cloned between Hind
III – Xba I sites in pRC-CMV vector; RelB, PSA and IL-8
expression constructs were purchased from Open Biosystems.
RelB catalog No.: MHS1010-7507797; PSA catalog No.:
MHS1010-9205472 ; IL-8 catalog No.: MHS1010-58052. The

PLoS ONE | www.plosone.org
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